J. L. Bainbridge & Co. Inc. Sells 2,104 Shares of Johnson & Johnson (NYSE:JNJ)

J. L. Bainbridge & Co. Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 135,137 shares of the company's stock after selling 2,104 shares during the period. Johnson & Johnson makes up about 2.2% of J. L. Bainbridge & Co. Inc.'s investment portfolio, making the stock its 20th biggest position. J. L. Bainbridge & Co. Inc.'s holdings in Johnson & Johnson were worth $22,411,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Tallon Kerry Patrick acquired a new stake in Johnson & Johnson in the fourth quarter worth $290,000. Brighton Jones LLC raised its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Shoker Investment Counsel Inc. raised its holdings in Johnson & Johnson by 1.2% in the fourth quarter. Shoker Investment Counsel Inc. now owns 18,571 shares of the company's stock worth $2,686,000 after purchasing an additional 226 shares during the period. Finally, Sentinel Trust Co. LBA raised its holdings in Johnson & Johnson by 11.9% in the fourth quarter. Sentinel Trust Co. LBA now owns 11,667 shares of the company's stock worth $1,687,000 after purchasing an additional 1,244 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Bank of America cut their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $152.58 on Tuesday. The company has a market cap of $367.12 billion, a P/E ratio of 16.97, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a fifty day simple moving average of $153.66 and a 200 day simple moving average of $153.86. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson's payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.